Objective To evaluate the clinical utility of the T-SPOT.TB test for patients with indeterminate results on the QFT-2G test. Materials and Methods Forty patients (10.6%) showed indeterminate results among 378 patients who underwent QFT-2G test because active TB disease was clinically suspected. T-SPOT.TB test was performed for these 40 patients before the initiation of antituberculous treatment. Results Forty patients (10.6%) were judged as showing indeterminate results on QFT-2G test because the positive control presented a lower IFN-γ level. Elderly patients (68.2 versus 57.7) or immunocompromised patients receiving immunosuppressive treatments and patients with a decrease in lymphocyte count, serum protein and albumin were more frequently recognized in the patients with indeterminate results compared to those with determinate results on QFT-2G test. T-SPOT.TB test could clearly demonstrate the results in 26 of the 40 patients (65.0%) with indeterminate results of QFT-2G test; these were divided into six patients with positive results and 20 with negative results of T-SPOT.TB test. Elderly patients (73.5 versus 64.3) or patients with underlying diseases such as malignant disease and those receiving immunosuppressive treatment and patients with hyponutritional conditions were more frequently recognized in the patients with indeterminate results compared to patients with determinate results on both tests. Conclusion We think it may be necessary to introduce T-SPOT.TB test to increase the diagnostic rate of TB disease including latent tuberculosis infection because indeterminate results of QFT-2G test might be further decreased using T-SPOT.TB test. Although 14 patients showed indeterminate results on both tests, the lymphocytes of these patients may not possess functional cytokine production activity.
Introduction
Two commercial interferon-gamma (IFN-γ) release assays, based on in vitro detection of IFN-γ released by T-cells in response to antigens specific to Mycobacterium tuberculosis (MTB) [QuantiFERON-TB Gold (QFT, Celestis Ltd, Victoria, Australia) and T-SPOT.TB (Oxford Immunotec, Oxford, UK)], are available for the diagnosis of tuberculosis (TB) infection (1) (2) (3) . QFT test is based on a whole-blood ELISA and has been approved for diagnostic use by US Food and Drug Administration (FDA) in the United States. However, T-SPOT.TB test is based on the enzyme-linked immunospot (ELISPOT) assay which has been approved for diagnostic use in Europe and is currently being assessed by the FDA. Although QFT test (QuantiFERON TB-2G: QFT-2G) has been used commercially in Japan since April 2005 for the diagnosis of TB infection, T-SPOT.TB test has not yet been approved. These tests are more specific in diagnosing TB infection (4) (5) (6) and equally or more sensitive in patients with immunosuppressive states than tuberculin skin test (TST). In previous reports concerning the comparison of both tests, while indeterminate results have been reported with a frequency of 5-40% for QFT test, the frequency of indeterminate results of T-SPOT.TB test (0-5.4%) have been lower than that of QFT test (7) (8) (9) (10) . The frequency results seem to be associated with an immunosuppressive state (11, 12) and with age (children younger five years old and elderly patients older than 80 years old).
Therefore, we investigated the following: 
Subjects and Methods

Subjects
Sample collection and TST
Each subject had a heparinized blood sample collected by venous puncture for whole blood IFN-γ assay. Blood samples were collected before administration of Mantoux TST. For TST, 0.1 mL of tuberculin PPD (Nippon BCG, equiva-lent to three tuberculin units of PPD solution) was injected intradermally into the volar aspect of the forearm, and the transverse induration diameter was measured 48 hours later. The TST results were interpreted according to the level of risk, as reported in current guidelines (13) .
QFT-2G test and T-SPOT.TB test
These two IFN-γ assays were performed according to the manufacturer's instructions (3, 14, 15) . The samples were incubated for 20 hours. QFT-2G test was performed for all patients suspected of TB disease. However, T-SPOT.TB test was performed immediately after obtaining indeterminate results of QFT-2G test for 40 patients who showed indeterminate results on QFT-2G test.
For QFT-2G test, the IFN-γ level of the negative control for each patient was subtracted from the levels obtained from the antigen-stimulated samples. The result was considered positive if the response to the specific antigens was 0.35 IU/mL, regardless of the level of the positive control; negative if the response to the specific antigens was <0.35 IU/mL and the IFN-γ level of the positive control was 0.5 IU/mL; and indeterminate if both antigen-stimulated samples were <0.35 IU/mL and the level of the positive control was <0.5 IU/mL (14) .
For T-SPOT.TB test, the spot count was performed using an automated ELISPOT Reader (AID systems, Strasberg, Germany). ESAT-6 or CFP-10 stimulated wells with at least five spots more than the negative control (where the negative control had fewer than or equal to five spots) were considered positive. In cases where the negative control well had six to 10 spots, the result was defined as positive when either the ESAT-6 or CFP-10 stimulated well contained at least twice as many spots as the negative control well. If the negative control well had >10 spots and/or <20 spots in the mitogen positive control wells, the result was considered to be indeterminate (3, 15) .
Statistical analysis
Information from the questionnaires, TST results and two IFN-γ assays results were subjected to statistical analysis. The number of patients without underlying diseases was significantly higher among patients with determinate results than among those with indeterminate results. There were no significant differences in other clinical characteristics between both groups. The decreases in white blood cell counts, lymphocyte counts, CD4 lymphocyte counts, serum protein and albumin were recognized significantly more frequently in patients with indeterminate results than in those with determinate results. However, there were no significant 
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Discussion
There are many reports on the clinical utility of two commercial interferon-γ release assays (QFT and T-SPOT.TB). Although these tests are similar in terms of antigens (ESAT-6 and CFP-10) and incubation time (overnight), the main differences involve the technique of IFN-γ detection (ELISA versus ELISPOT) and the specimens used (whole blood versus mononuclear cells). Of these tests, the QFT test seems to be more convenient and easier to perform than T-SPOT. TB test because QFT test uses whole blood rather than mononuclear cells and ELISA is more commonly available and simpler than ELISPOT. However, ELISPOT is sufficiently sensitive to detect single IFN-γ-producing cells. Richeldi reported on the sensitivity and specificity of these two blood tests (4) . The sensitivity of T-SPOT.TB test (83-97%) was superior to that of QFT test (59-89%), while the specificity of QFT test (96-98%) was similar to that of T. SPOT.TB test (100%) for the diagnosis of latent TB infection (2, 17, 18) Only QFT test produces many indeterminate results because of the low sensitivity. In this study, 40 (10.6%) of 378 patients suspected of TB infection demonstrated indeterminate results due to positive control failure on QFT-2G test according to CDC guidelines (14) . In a previous report, Ferrara et al (9) noted that indeterminate results of QFT test occurred due to positive control failure in 21% of patients tested in routine clinical microbiological laboratories and that indeterminate results were significantly overrepresented among patients receiving immunosuppressive treatments. A similar result was confirmed in a prospective study of 393 individuals and indeterminate results appeared in 11% (10) . However, there was no speculation on the reason for this finding.
Through this study, we first demonstrated the importance of advanced age and non-respiratory diseases receiving immunosuppressive treatment as clinical characteristics that can promote indeterminate results on QFT-2G test. Otherwise, laboratory findings of the decrease of lymphocyte counts including CD4 lymphocyte counts or the decrease of serum protein including albumin could significantly influence the risk of indeterminate results compared to determinate results. However, there was no significant difference between the two groups with regard to the microbiological findings or radiological findings such as extension of the lesions.
To reduce the frequency of obtaining indeterminate results on QFT-2G test, we examined T-SPOT.TB test for patients with indeterminate results considering the higher sensitivity of the diagnosis of TB infection in this study. Subsequently, two-thirds of these patients showed determinate results instead of indeterminate results by correcting the count of mononuclear cells due to T-SPOT.TB test. However, the remaining one-third of patients with indeterminate results on QFT-2G test showed indeterminate results on T-SPOT.TB test, even when we performed two IFN-γ release assays repeatedly. Indeterminate results may arise from the following three findings: 1) insufficient response of the mitogen positive control, 2) nonspecific background staining in the wells, 3) nonspecific interferon-γ release by the mononuclear cells in the well (resulting in a high nil-control spot count). These effects may be the result of the following three reasons; 1) the effect on the patient's immune system may cause a weak response to the mitogen positive control yielding a response that is insufficiently strong to measure (19) , 2) degradation of the patient's sample due to transport, affecting the viability of the T-cells within the sample (20) , and 3) technical errors in the performance of the test by laboratory personnel, which may result in all three indeterminate reactions. The fact that indeterminate responses were not resolved in all retested cases suggests that the first cause was likely to occur in most indeterminate reactions. The first cause may be speculated to involve functional insufficiency of mononuclear cells producing various kinds of cytokines rather than a decrease in the number of mononuclear cells because both tests showed indeterminate results due to positive control failure. As for clinical characteristics, patients showing indeterminate results on both tests were most frequently elderly patients or patients with severe underlying diseases such as malignant disease or those receiving immunosuppressive treatment. Because there are no previous reports demonstrating the decrease in the functional activity of mononuclear cells for these patients suspected of TB disease, it will be necessary to investigate the functional activity of mononuclear cells of these patients in future.
In
conclusion, because only QFT-2G test has been commonly commercialized for the diagnosis of TB infection and T-SPOT.TB test has not yet been adopted, we would like to support the approval of T-SPOT.TB test as a diagnostic method as soon as possible by the Ministry of Health and
Welfare in Japan based on the findings of this study.
